Solvents may act as estrogen blockers in development of Parkinson disease

Annals of Neurology

Volumn 72, Issue 3, 2012, Pages 477-

  Brenner, Steven ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ANTIESTROGEN; CARBON TETRACHLORIDE; CHLORPYRIFOS; ESTROGEN; METHOMYL; PESTICIDE; PROPARGITE; SOLVENT; TETRACHLOROETHYLENE; TRICHLOROETHYLENE; UNCLASSIFIED DRUG;

BRAIN; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG METABOLISM; HUMAN; LETTER; MEDIATOR; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SIGNAL TRANSDUCTION;

ESTROGEN ANTAGONISTS; HUMANS; PARKINSON DISEASE; SOLVENTS;

EID: 84867100749     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23625     Document Type: Letter

References (5)

1. Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Ann Neurol 2012; 71: 776-784.
2. Kester MH, Bulduk S, van Torr H, et al. Potent inhibition of estrogen sulfotransferase by hydroxylated metabolites of polyhalogenated aromatic hydrocarbons reveals alternative mechanism for estrogenic activity of endocrine disruptors. J Clin Endocrinol Metab 2002; 87: 1142-1150.
3. Gatto N, Cockburn M, Bronstein J, et al. Well-water consumption and Parkinson's disease in rural California. Environ Health Perspect 2009; 117: 1912-1918.
4. Vegeto E, Belcredito S, Ghisletti S, et al. The endogenous estrogen status regulates microglia reactivity in animal models of neuroinflammation. Endocrinology 2006; 147: 2263-2272.
5. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 2009; 30: 293-342.